Dr. Gail Naughton, world-renowned authority on the multi-billion dollar regenerative medicine market, joins HippoFi as Head of Regenerative Therapeutics and Commercialization
Scientist, inventor, business expert and holder of more than 140 patents will advance PUR Biologics’ regenerative therapeutic patent portfolio to address unmet needs in the $200 billion osteoarthritis, pain and cartilage and spine regeneration markets.
IRVINE CA., November 7, 2023 – OrthoSpineNews – HippoFi, Inc. (OTCPK: ORHB) is proud to announce the appointment of the world’s foremost authority and pioneer in regenerative medicine, Gail Naughton, MBA, Ph.D, as the “Head of Regenerative Therapeutics and Commercialization.”
Recognized worldwide, Dr. Naughton was awarded the 27th annual National Inventor of the Year by the Intellectual Property Owners Association in honor of her groundbreaking work in tissue engineering and regenerative medicine. Dr. Naughton has been a driving force in regenerative medicine for more than 35 years and, as founder of Advanced Tissue Sciences and Histogen, has a proven track record in monetizing important cell-based therapies and bioengineered tissue technologies. Although it is known for taking four products from concept, through FDA approval, to market launch; and taken two companies to a NASDAQ stock exchange listing, she has had broad success in commercializing major brands that are still widely sold today by establishing partnerships and strategic business alliances with several industry giants, including: NYSE Company Allergan (recently purchased by AbbVie for $63B), NYSE company Smith & Nephew, NYSE company Medtronic, and Inamed Corporation (also owned by AbbVie).
“I am thrilled and honored to join the visionary HippoFi team and work together to transform healthcare by developing and commercializing life-changing regenerative medicine solutions for unmet medical needs,” said Gail Naughton, MBA, Ph.D – Head of Regenerative Therapeutics and Commercialization.
Dr. Naughton has served on the board of directors of several public and private companies since 1988. She currently serves as chair of the board of directors of the La Jolla Institute, executive chair of BioHIP, a member of the boards of NASDAQ, Therapeutics MD, and NYSE company CelSci, and serves on the boards of International Business and Fowler College of Business at SDSU. In addition to serving for eleven years on the board of the Toronto-based, publicly funded Center for the Commercialization of Regenerative Medicine (CCRM), she also served for several years on the bioengineering advisory board of John Hopkins, UCSD, MIT and Georgia Tech. Dr. Naughton served as dean of the College of Business Administration at SDSU from 2002 to 2011 and received her Ph.D. and MS from NYU Medical Center and an MBA from UCLA.
“Dr. Naughton is a globally recognized, accomplished entrepreneur with many proven track records, visionary talent and unparalleled experience that will be extremely valuable to HippoFi’s continued growth and success,” said CJ Wiggins, MBA – Founder, Executive Chairman and CEO of HippoFi. “As a pioneer in our industry, adding her expertise to our experienced team not only helps us quickly commercialize and monetize our patented technologies, but also validates the tremendous market value of our patent portfolio and strengthens HippoFi as a leader in the market for regenerative therapies. ”
About PUR Biologics
PUR Biologics, a wholly owned subsidiary of HippoFi, Inc. (OTCPK: ORHB), is a leading biologics company committed to supporting surgeons and hospitals in providing the best care to their patients. PUR Biologics’ full line of biological products currently includes: advanced allografts and demineralized extracellular matrices (dECM), innovative synthetic solutions, cellular-derived tissues and a future of next-generation regenerative stem cell and growth factor-driven therapies for the treatment of osteoarthritis and cartilage regeneration.
About HippoFi, Inc.
HippoFi, Inc. delivers its breakthrough healthcare innovations through an extensive sales channel network while deploying first-to-market solutions in the multi-billion dollar biotech, fintech and artificial intelligence (AI) markets. HippoFi consists of three segments: Regenerative Therapeutics, Digital Payments and AI, which use the same customer channels to commercialize solutions, increase revenue and improve patient outcomes.
HippoFi, Inc. is publicly traded under the symbol: ORHB and is headquartered in Irvine, California. For more information, please visit: www.HippoFi.com and www.PURbiologics.com.
Contact
HippoFi, Inc.
949-323-2330
info@hippofi.com
